Criscuolo Elena, Giuliani Benedetta, Ferrarese Roberto, Ferrari Davide, Locatelli Massimo, Clementi Massimo, Mancini Nicasio, Clementi Nicola
Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, Milan, Italy.
SCVSA Department, University of Parma, Parma, Italy.
J Med Virol. 2023 Mar;95(3):e28643. doi: 10.1002/jmv.28643.
Since early May 2022, some monkeypox virus (MPXV) infections have been reported from countries where the disease is not endemic. Within 2 months, the number of patients has increased extensively, becoming the most considerable MPXV outbreak described. Smallpox vaccines demonstrated high efficacy against MPXVs in the past and are considered a crucial outbreak control measure. However, viruses isolated during the current outbreak carry distinct genetic variations, and the cross-neutralizing capability of antibodies remains to be assessed. Here we report that serum antibodies elicited by first-generation smallpox vaccines can neutralize the current MPXV more than 40 years after vaccine administration.
自2022年5月初以来，一些非猴痘流行国家报告了猴痘病毒（MPXV）感染病例。在两个月内，患者数量大幅增加，成为有记录以来最严重的猴痘疫情。过去，天花疫苗对猴痘病毒显示出高效力，被视为控制疫情的关键措施。然而，此次疫情期间分离出的病毒具有明显的基因变异，抗体的交叉中和能力仍有待评估。在此，我们报告第一代天花疫苗诱导产生的血清抗体在接种疫苗40多年后仍能中和当前的猴痘病毒。
